Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUSZ Therapeutic Study for COVID-19
NCT05925140Phase 1Recruiting
- Sponsor
- Lebanese University
- Start
- Mar 2020
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of remdesivir, lopinavir + ritonavir and tocilizumab in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Lebanese University. Primary endpoints: Mortality rate at 28 days and Clinical improvement rate at 28 days. Started Mar 2020; status: recruiting.
02
Drugs
remdesivirlopinavir + ritonavirtocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05925140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05925140.